⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PBM News
Psyence Biomedical Ltd. Common Shares
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
globenewswire.com
PBM
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
globenewswire.com
PBM
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
globenewswire.com
PBM
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
globenewswire.com
PBM
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
globenewswire.com
PBM
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
globenewswire.com
FOLD
PBM
PRPH
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
globenewswire.com
PBM
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
globenewswire.com
PBM
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
globenewswire.com
PBM
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
globenewswire.com
PBM